Nothing Special   »   [go: up one dir, main page]

Benson et al., 2014 - Google Patents

Colon cancer, version 3.2014

Benson et al., 2014

Document ID
2929483218949482114
Author
Benson A
Venook A
Bekaii-Saab T
Chan E
Chen Y
Cooper H
Engstrom P
Enzinger P
Fenton M
Fuchs C
Grem J
Hunt S
Kamel A
Leong L
Lin E
Messersmith W
Mulcahy M
Murphy J
Nurkin S
Rohren E
Ryan D
Saltz L
Sharma S
Shibata D
Skibber J
Sofocleous C
Stoffel E
Stotsky-Himelfarb E
Willett C
Gregory K
Freedman-Cass D
Publication year
Publication venue
Journal of the National Comprehensive Cancer Network

External Links

Snippet

The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease, and survivorship. This portion of the guidelines focuses on the use …
Continue reading at jnccn.org (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407Specifically defined cancers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Benson et al. Colon cancer, version 3.2014
Benson et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology
Benson et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology
Benson et al. Colon cancer
Maron et al. Targeted therapies for targeted populations: anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma
Petrylak et al. Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant prostate cancer: a phase I study
Collins et al. Product review: avelumab, an anti-PD-L1 antibody
Dienstmann et al. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials
Ricciardi et al. NSCLC and HER2: between lights and shadows
Battaglin et al. The role of tumor angiogenesis as a therapeutic target in colorectal cancer
Lombardi et al. Adjuvant colon cancer chemotherapy: where we are and where we'll go
Martini et al. Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: what does still need to be addressed?
Lorch et al. Identification of recurrent activating HER2 mutations in primary canine pulmonary adenocarcinoma
JP2016105096A (en) Biomarkers and methods of treatment
CN102216331A (en) Treatment method
Benson et al. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Burgenske et al. Establishment of genetically diverse patient-derived xenografts of colorectal cancer
De Mattos-Arruda et al. Development of molecular biomarkers in individualized treatment of colorectal cancer
JP2017516458A (en) Cancer treatment with c-met antagonist and correlation with HGF expression of c-met antagonist
Ruiz-Banobre et al. Predictive biomarkers in metastatic colorectal cancer: A systematic review
Ha et al. Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma
Smithy et al. Pancreas cancer: therapeutic trials in metastatic disease
Cheetham et al. New agents for the treatment of advanced bladder cancer
Zhang et al. Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study)
Taieb et al. Treatment of gastric adenocarcinoma: A rapidly evolving landscape